Matrix Gla protein as natural inhibitor of vascular calcification and potential treatment target

1. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–952.

2. Greenland P et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation 2007; 115: 402–426.

3. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med 2004; 164: 1285–1292.

4. Rumberger JA, Simons DB, Fitzpatrick LA et al. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation 1995; 92: 2157–2162.

5. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657–671.

6. Demer LL, Tintut Y. The leading edge of vascular calcification. Trends Cardiovasc Med 2015; 25: 275–277.

7. Price PA, Urist MR, Otawara Y. Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun 1983; 117: 765–771.

8. Shanahan CM, Proudfoot D, Farzaneh-Far A, Weissberg PL. The role of Gla proteins in vascular calcification. Crit Rev Eukaryot Gene Expr 1998; 8: 357–375.

9. Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature 1997; 386: 78–81.

10. Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin k. Thromb Haemost 2008; 100: 593–603.

11. Kruger T, Oelenberg S, Kaesler N et al. Warfarin induces cardiovascular damage in mice. Arterioscler Thromb Vasc Biol 2013; 33: 2618–2624.

12. Cranenburg EC, Koos R, Schurgers LJ et al. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost 2010; 104: 811–822.

13. Schurgers LJ, Spronk HM, Skepper JN et al. Post-translational modifications regulate matrix Gla protein function: Importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost 2007; 5: 2503–2511.

14. Cranenburg EC, Brandenburg VM, Vermeer C et al. Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost 2009; 101: 359–366.

15. Mayer O jr., Seidlerová J, Vaněk J et al. The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease. Int J Cardiol 2016; 203: 916–922.

16. Mayer O jr., Seidlerová J, Wohlfahrt P et al. Desphospho-uncarboxylated matrix Gla protein is associated with increased aortic stiffness in a general population. J Hum Hypertens 2016 Jul; 30(7): 418–423.

17. Theuwissen E, Smit E, Vermeer C. The role of vitamin K in soft-tissue calcification. Adv Nutr 2012; 3: 166–173.

18. Dalmeijer GW, van der Schouw YT, Vermeer C et al. Circulating matrix Gla protein is associated with coronary artery calcification and vitamin K status in healthy women. J Nutr Biochem 2013; 24: 624–628.

19. van den Heuvel EG, van Schoor NM, Lips P et al. Circulating uncarboxylated matrix Gla protein, a marker of vitamin K status, as a risk factor of cardiovascular disease. Maturitas 2014; 77: 137–141.

20. Schurgers LJ, Barreto DV, Barreto FC et al. The circulating inactive form of matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: A preliminary report. Clin J Am Soc Nephrol 2010; 5: 568–575.

21. Ueland T, Gullestad L, Dahl CP et al. Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. J Intern Med 2010; 268: 483–492.

22. Ueland T, Dahl CP, Gullestad L et al. Circulating levels of non-phosphorylated undercarboxylated matrix gla protein are associated with disease severity in patients with chronic heart failure. Clin Sci (Lond) 2011; 121: 119–127.

23. Mustonen E, Pohjolainen V, Aro J et al. Upregulation of cardiac matrix Gla protein expression in response to hypertrophic stimuli. Blood Press 2009; 18: 286–293.

24. Bostrom K, Zebboudj AF, Yao Y et al. Matrix Gla protein stimulates VEGF expression through increased transforming growth factor-beta1 activity in endothelial cells. J Biol Chem 2004; 279: 52904–52913.

25. Yao Y, Zebboudj AF, Shao E et al. Regulation of bone morphogenetic protein-4 by matrix Gla protein in vascular endothelial cells involves activin-like kinase receptor 1. J Biol Chem 2006; 281: 33921–33930.

26. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318–1327.

27. Pivin E, Ponte B, Pruijm M et al. Inactive matrix Gla-protein is associated with arterial stiffness in an adult population-based study. Hypertension 2015; 66: 85–92.

28. Gast GC, de Roos NM, Sluijs I et al. A high menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovasc Dis 2009; 19: 504–510.

29. Geleijnse JM, Vermeer C, Grobbee DE et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The rotterdam study. J Nutr 2004; 134: 3100–3105.

30. Beulens JW, Bots ML, Atsma F et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis 2009; 203: 489–493.

31. Schurgers LJ, Spronk HM, Soute BA et al. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007; 109: 2823–2831.

32. Braam LA, Hoeks AP, Brouns F et al. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost 2004; 91: 373–380.

33. Shea MK, O'Donnell CJ, Hoffmann U et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr 2009; 89: 1799–1807.

34. Knapen MH, Braam LA, Drummen NE et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. Thromb Haemost 2015; 113: 1135–1144.